SCI Ventures — Full Portfolio
12 tracked investments · listed companies and verified rows first
NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair.
BiotechDeep TechHealthtechMedical Devices
Harold Punnett(Co-founder)inJerry Silver(Co-founder)William Adams(Executive Officer)Paul Brennan(Director, Executive Officer)inDaniel Mikol(Executive Officer)inAdam Rogersin
Co-investorsCWRU Technology Ventures
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+7 more
Developing targeted gene therapy platform for specific neuronal populations, with initial focus on neurogenic detrusor overactivity in spinal cord injury and neurodegenerative diseases.
Healx is an AI-powered biotech company that discovers and develops treatments for rare diseases.
AI & Machine LearningBiotechDigital HealthHealthtechCambridge, GB
Tim Guilliams(Co-founder & CEO)in
Co-investorsAmadeus Capital PartnersBalderton CapitalCambridge Angels groupIntel Capital
Leader in spinal cord stimulation technology using targeted programmed stimulation to restore movement and function, with first FDA approval expected in 2024.
HealthtechNew York, US
Benjamin Rapoport(President, Chief Science Officer)inMichael Mager(Chief Executive Officer)inCraig Mermel(President and Chief Product Officer)inMIchael Kaswan(Chief Financial Officer)
BoardEric M. Attias(Director)Howard Morgan(Director)in
Co-investorsAlumni VenturesB Capital GroupBasecamp FundForepont Capital PartnersSteadview Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.